key: cord-0882921-gfii16ub authors: Arbyn, Marc; Gultekin, Murat; Morice, Philippe; Nieminen, Pekka; Cruickshank, Maggie; Poortmans, Philip; Kelly, Daniel; Poljak, Mario; Bergeron, Christine; Ritchie, David; Schmidt, Dietmar; Kyrgiou, Maria; Van den Bruel, Ann; Bruni, Laia; Basu, Partha; Bray, Freddie; Weiderpass, Elisabete title: The European response to the WHO call to eliminate cervical cancer as a public health problem date: 2020-08-04 journal: Int J Cancer DOI: 10.1002/ijc.33189 sha: aeab6c42ea2da31c6a9f87093bbfbe58558b9789 doc_id: 882921 cord_uid: gfii16ub The age‐standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women‐years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All European nations should, by 2030, reach at least 90% HPV vaccine coverage among girls by the age of 15 years and also boys, if cost‐effective; they should introduce organised population‐based HPV‐based screening and achieve 70% of screening coverage in the target age group, providing also HPV testing on self‐samples for nonscreened or underscreened women; and to manage 90% of screen‐positive women. To guide member states, a group of scientific professional societies and cancer organisations engage to assist in the rollout of a series of concerted evidence‐based actions. European health authorities are requested to mandate a group of experts to develop the third edition of European Guidelines for Quality Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening and to monitor the progress towards the elimination goal. The occurrence of the COVID‐19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. In the immediate postepidemic phase, health professionals should focus on high‐risk women and adhere to cost‐effective policies including self‐sampling. coverage in the target age group, providing also HPV testing on self-samples for nonscreened or underscreened women; and to manage 90% of screen-positive women. To guide member states, a group of scientific professional societies and cancer organisations engage to assist in the rollout of a series of concerted evidence-based actions. European health authorities are requested to mandate a group of experts to develop the third edition of European Guidelines for Quality Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening and to monitor the progress towards the elimination goal. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. In the immediate postepidemic phase, health professionals should focus on high-risk women and adhere to cost-effective policies including self-sampling. 1 These estimates concern the European region as defined by the United Nations. The incidence rates vary widely within Europe, with agestandardised incidence rates (ASIR) ranging from less than 5/100000 in Malta (3.5), Switzerland (3.8) and Finland (4.7) to ASIRs over 20/100000 in Latvia (25.0), Bosnia Herzegovina (23.9), Estonia (22.5) , Moldova (21.4) , Serbia (20.3) and Bulgaria (20. 3) (see Figure 1 ; Table 1 ). There is a clear Western to Eastern Europe trend with ASIRs lower than 10/100000 and age-standardised mortality rates (ASMR) lower than 3/100000 in Northern, Southern and Western Europe, compared with ASIR of 16/100000 and ASMR of 6/100000 in Central-Eastern Europe. In the 28 member states of the European Union (EU) (as defined in 2018, still including the United Kingdom), the average age-standardised incidence and mortality rates are 10.0 and 3.1 per 100 000 women-years, respectively. For a more detailed assessment of the burden of cervical cancer in Europe vs other continents and on the methodology of estimation, we refer to a recent publication in Lancet Global Health 1 and the description of the sources and methods used in developing the GLOBOCAN estimates. 2,3 Historically, screening by detection and treatment of cervical precancer lesions identified through cytological examination of Pap smears has resulted in a significant reduction in cervical cancer incidence and mortality. [4] [5] [6] The implementation of the European Guidelines for Quality Assurance of Cervical Cancer Screening has played a pivotal role in achieving this result. 7 However, recent trend analyses indicate that even in countries with well-organised cytology-based screening programmes, cervical cancer incidence rates have stopped decreasing or are even increasing. 1, [8] [9] [10] This phenomenon might be explained by an increased exposure to oncogenic types of the human papillomavirus (HPV), lower screening coverage rates, particularly among young women, and the limitations of cytology-based screening. 1 Therefore, new effective preventive tools, which have become available in the last decade, should be implemented without delay. Strong evidence has accumulated, indicating that primary prevention by vaccination against the main carcinogenic HPV types is safe and protects well against future HPV infection and associated anogenital precancer in young females and males. 11 Table 2 ). The European Centre for Disease Control and Prevention in its recently released guidance on HPV vaccination in EU countries stated that a gender neutral vaccination becomes increasingly cost-effective in the presence of persistently suboptimal coverage of females with reducing vaccine price. 16 However, in countries with HPV vaccination coverage of 80% or higher among girls, boys are already well protected by herd-immunity, which renders gender-neutral vaccination less cost-effective. Interventions to increase vaccination coverage among girls where it is low might be more cost-effective than adding vaccination of boys. 17 Intervention research aiming to identify effective strategies to increase HPV vaccination uptake and implementation of such strategies should be promoted. Regarding secondary prevention, randomised population-based trials have demonstrated that HPV-based screening is more performant in protecting against incident cervical precancer and cancer than cytology. 18, 19 In addition, screening with validated polymerase chain reaction-based HPV assays offers the advantage that it can be performed on a specimen collected by the woman herself. The offer of self-sampling devices has been shown to be performant in reaching underscreened populations. 20, 21 Neither the World Health Organisation (WHO) nor EU guidelines recommend screening by cotesting with HPV and cytology. 22, 23 HPV infection is mainly sexually transmitted and this fact entails sensitive and tailored communications, including appropriate health education, to the general public as well as to individual women needing counselling in order to reduce stigma, shame and worry, by taking into account the particular social and cultural background. 24 Recognising that cervical cancer affects many women at an age when they have important economic and familial responsibilities, and acknowledging its high level of preventability, has motivated the WHO Director General to launch an appeal to all countries of the world to eliminate this disease as a public health problem. 26 It is estimated that by vaccinating 90% of girls before they reach the age • Across all European countries, 90% of women with Grade III cervical intraepithelial neoplasia should be treated within 3 months. All women with diagnosed cervical cancer should have access to appropriate oncological services including palliative care for incurable cases. • All European country cancer plans should include actions towards achieving these treatment goals. • Guidelines on HPV vaccination and cervical cancer screening should also review the relevance of ablation (cryotherapy, thermal ablation) as a simple, safe and efficacious technique to treat cervical precancers, especially in younger women in Europe. SARS-CoV-2 have interrupted the implementation of current preventive programmes and delayed new activities planned in Europe and elsewhere. 28 Concerns related to cervical cancer control amidst the COVID-19 pandemic and the period thereafter are addressed in Box 6. As part of the coordination role that the EU should play in assisting member states to combat cancer, a public monitoring and reporting system should be established with respect to EU member state cancer plan items, similar to Although waiting for an official mandate from the EU Commission, a large group of professional societies and cancer organisations are engaged and willing to assist the WHO and European health authorities to achieve the laudable goal of eliminating cervical cancer. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence Trends of cervical cancer mortality in the member states of the European Union European Guidelines for Quality Assurance in Cervical Cancer Screening. Luxembourg: Office for Official Publications of the European Communities Cervical cancer has increased in Sweden in women who had a normal cell sample Disease burden of human papillomavirus infection in The Netherlands, 1989-2014: the gap between females and males is diminishing. Cancer Causes Control Is the recent increase in cervical cancer in women aged 20-24years in England a cause for concern Prophylactic vaccination against human papillomaviruses to prevent cervical cancer its precursors Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection Efficacy of Quadrivalent HPV vaccine against HPV infection and disease in males HPV vaccine against anal HPV infection and anal intraepithelial neoplasia Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis the Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem European guidelines for quality Assurance in Cervical Cancer Screening. Second edition-summary document Socio-economic variations in anticipated adverse reactions to testing HPV positive: implications for the introduction of primary HPV-based cervical screening Vaccine counseling: a content analysis of patient-physician discussions regarding human papilloma virus vaccine Director-General Calls for all Countries to Take Action to Help End the Suffering Caused by Cervical Cancer Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study Tackling cervical cancer in Europe amidst the COVID-19 pandemic European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination Expert consensus from the Italian Society for Colposcopy and Cervico-Vaginal Pathology (SICPCV) for colposcopy and outpatient surgery of the lower genital tract during the COVID-19 pandemic The European response to the WHO call to eliminate cervical cancer as a public health problem Cancer and the International Agency for Research on Cancer are acknowledged for financial contributions. https://orcid.org/0000-0001-7807-5908Murat